Foley & Lardner LLP announced today that five of its attorneys have been recognized in the Chambers Global 2021 guide. In addition, the firm was recognized for three practice areas in the U.S. and Mexico.
- Kathryn Trkla was recognized for Capital Markets: Derivatives and Capital Markets: Derivatives: Mainly Regulatory in the U.S.
- John Eliason and Thomas Hoffman were recognized for Projects: Renewables & Alternative Energy in the U.S.
- Fernando Camarena Cardona and Roberto Arena Reyes Retana were recognized for Tax: Non-Contentious in Mexico.
The firm was recognized for its Projects: Power & Renewables: Transactional and its Projects: Renewables & Alternative Energy practices in the U.S. and its Tax: Non-Contentious practice in Mexico.
To compile its annual lists, Chambers and Partners conducted thousands of interviews with attorneys and their clients in a wide range of industries. Interview participants were asked to recommend attorneys and firms they use most often for top-tier legal work.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”